Journal ArticleJ Intensive Care Med · September 9, 2024
Background: Patients with end-stage liver disease (ESLD) often require Intensive Care Unit (ICU) admission during the disease trajectory, but aggressive medical treatment has not resulted in increased quality of life for patients or caregivers. Methods: Th ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · September 2024
BACKGROUND: Malnutrition in cirrhosis is associated with poor outcomes, leading to guidelines for a high protein, low sodium diet; however, there is no guidance regarding the implementation of diet education in clinical practice. METHODS: A mixed methods s ...
Full textLink to itemCite
Journal ArticleAlcohol Clin Exp Res (Hoboken) · August 2024
BACKGROUND: There is a lack of randomized controlled trials of behavioral interventions and process-level research related to alcohol reduction among patients with chronic liver disease (e.g., hepatitis C viral (HCV) infection). We conducted a process-leve ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · July 16, 2024
OBJECTIVE: To evaluate order completion after telehealth compared with in-person encounters. BACKGROUND: Completion of ordered testing, including laboratories and imaging, is an important aspect of successful outpatient care of patients with liver disease. ...
Full textLink to itemCite
Journal ArticleHepatol Commun · July 1, 2024
BACKGROUND: Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage and predict PSC-related fi ...
Full textLink to itemCite
Journal ArticleAm J Transplant · March 2024
Curative hepatitis C virus (HCV) therapy has increased transplantation from HCV-infected nucleic acid test-positive donors to HCV-uninfected recipients (D+/R-). We evaluated outcomes of early and late HCV treatment among D+/R- nonliver organ transplants. P ...
Full textLink to itemCite
Journal ArticleLiver Transpl · November 1, 2023
Disparities exist in referral and access to the liver transplant (LT) waitlist, and social determinants of health (SDOH) are increasingly recognized as important factors driving health inequities, including in LT. The SDOH of potential transplant candidate ...
Full textLink to itemCite
Journal ArticleHepatol Commun · September 1, 2023
BACKGROUND: The presence of workplace bias around child-rearing and inadequate parental leave may negatively impact childbearing decisions and sex equity in hepatology. This study aimed to understand the influence of parental leave and child-rearing on car ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · June 2023
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a major unmet medical need in clinical hepatology. Cilofexor is a nonsteroidal farnesoid X receptor agonist being evaluated for the treatment of PSC. Here, we describe the safety and preliminary ef ...
Full textLink to itemCite
Journal ArticleJ Gastroenterol Hepatol · June 2023
BACKGROUND AND AIM: Staining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described. METHODS: Biopsies were collected from a large cohort of ...
Full textLink to itemCite
Journal ArticleHepatol Commun · June 1, 2023
BACKGROUND: Prospective data regarding the safety and yield of liver biopsy in both adults and children with chronic hepatitis B are limited. The aim of this study is to report safety, yield, and complication rates among adults and children with chronic he ...
Full textLink to itemCite
Journal ArticleJGH Open · April 2023
BACKGROUND AND AIM: Hospice is underutilized in the management of patients with end-stage liver disease and may improve the patient experience at the end of life. This study aims to create a novel prognostic scale to accurately predict 6-month mortality to ...
Full textLink to itemCite
Journal ArticleGut · March 2023
OBJECTIVE: In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confir ...
Full textLink to itemCite
Journal ArticleLiver Int · March 2023
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with a high risk of cardiovascular disease. Whether risk scores developed in the general population accurately assess cardiovascular risk in the NAFLD population is unknown. This ...
Full textLink to itemCite
Journal ArticleHepatology communications · March 2023
BackgroundEmployment outcomes after liver transplant (LT) over the past decade have not been described.MethodsLT recipients ages 18-65 from 2010-2018 were identified in Organ Procurement and Transplantation Network data. Employment within ...
Full textCite
Journal ArticleClin Liver Dis · February 2023
Abnormal liver tests are common after liver transplantation. The differential diagnosis depends on the clinical context, particularly the time course, pattern and degree of elevation, and donor and recipient factors. The perioperative period has distinct c ...
Full textLink to itemCite
Journal ArticleHepatology · January 1, 2023
BACKGROUND AND AIMS: Telehealth may be a successful strategy to increase access to specialty care for liver disease, but whether the areas with low access to care and a high burden of liver-related mortality have the necessary technology access to support ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · December 2022
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease, and many patients ultimately require liver transplantation (LT). PSC also confers an increased risk of malignancies, including cholangiocarcinoma (CCA) and colorectal ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · November 2022
GOAL: The goal of this study was to determine the accuracy of Model of End-stage Liver Disease-Sodium (MELD-Na) in predicting 6-month mortality for patients listed for liver transplantation on the United Network of Organ Sharing (UNOS) waitlist. BACKGROUND ...
Full textLink to itemCite
Journal ArticleHepatology · September 2022
BACKGROUND AND AIMS: Treatment of immune-tolerant (IT) children and adults with combined peginterferon alfa-2a and entecavir results in a decline in serum HBeAg and HBsAg concentrations but rarely results in loss of HBeAg or sustained off-treatment respons ...
Full textLink to itemCite
ConferenceHepatology · May 2022
BACKGROUND AND AIMS: Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver-related complications in patien ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · February 2022
BACKGROUND & AIMS: Achieving sustained virologic response (SVR) among patients with hepatitis C virus (HCV) leads to patient reported outcome (PRO) improvement. We aimed to assess the long-term post-SVR PRO trends in HCV patients with cirrhosis. METHODS: P ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · January 2022
BACKGROUND AND AIMS: The coronavirus disease 2019 (COVID-19) pandemic resulted in a rapid expansion of telehealth services in hepatology. However, known racial and socioeconomic disparities in internet access potentially translate into barriers for the use ...
Full textLink to itemCite
Journal ArticleBMJ Open Gastroenterol · January 2022
OBJECTIVE: The transjugular intrahepatic portosystemic shunt (TIPS) procedure is an important intervention for management of complications of portal hypertension. The objective of this study was to identify predictors of mortality from the TIPS procedure w ...
Full textLink to itemCite
Journal ArticleHepatology · December 2021
BACKGROUND AND AIMS: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. APPROACH AND RESULTS: We conducted a ...
Full textLink to itemCite
Journal ArticleAliment Pharmacol Ther · December 2021
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has high morbidity and mortality related to cardiovascular disease (CVD), but statins have been historically underutilised in these patients due to concern for hepatotoxicity. AIMS: To characterise tren ...
Full textLink to itemCite
Journal ArticleCurrent Hepatology Reports · December 1, 2021
Purpose of Review: To summarize recommendations and common practices for long-term surveillance after hepatitis C cure. Recent Findings: Patients with advanced fibrosis and cirrhosis have continued risk of the complications of portal hypertension and hepat ...
Full textCite
Journal ArticleMol Genet Metab Rep · December 2021
INTRODUCTION: A deficiency of glycogen debrancher enzyme in patients with glycogen storage disease type III (GSD III) manifests with hepatic, cardiac, and muscle involvement in the most common subtype (type a), or with only hepatic involvement in patients ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Viral Hepat · November 2021
Hepatitis B e antigen (HBeAg) is a soluble viral protein in plasma of patients with hepatitis B virus infection. HBeAg loss is an important first stage of viral antigen clearance. We determined the rate and predictors of HBeAg loss in a North American coho ...
Full textLink to itemCite
Journal ArticleNurs Sci Q · October 2021
The authors describe a family's adaptive challenges and adaptive work during a family member's treatment for Chronic Hepatitis C. We audiorecorded index and final clinical visits and interviewed participants (patients and providers) following the visits. W ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · September 2021
BACKGROUND: Patients with chronic hepatitis C and risky/harmful alcohol use experience poor outcomes. Granular data evaluating whether alcohol counseling during hepatitis C treatment impacts longitudinal alcohol consumption are lacking. AIMS: To evaluate w ...
Full textLink to itemCite
Journal ArticleClin Imaging · September 2021
PURPOSE: Proton pump inhibitor (PPI) use is a potential risk factor for hepatic encephalopathy (HE), but few studies have examined the effect on post-TIPS HE. The purpose of this study was to determine whether PPIs are associated with increased rates of po ...
Full textLink to itemCite
Journal ArticleJ Vasc Interv Radiol · July 2021
PURPOSE: To determine whether socioeconomic status (SES) is associated with hepatic encephalopathy (HE) risk after transjugular intrahepatic portosystemic shunt (TIPS) creation. MATERIALS AND METHODS: This single-institution retrospective study included 36 ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · July 2021
BACKGROUND: In chronic hepatitis B (CHB) viral infection, e antigen positivity (HBeAg+) is associated with high levels of viral replication and infectivity. Furthermore, HBeAg-positive CHB is associated with a liver disease spectrum ranging from none to se ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · June 2021
BACKGROUND & AIMS: Serum alkaline phosphatase (ALP) and the enhanced liver fibrosis (ELF) score are used as endpoints in trials of patients with primary sclerosing cholangitis (PSC). We aimed to quantify inter- and intra-individual variation in levels of A ...
Full textLink to itemCite
Journal ArticleEur Radiol · June 2021
OBJECTIVES: The LI-RADS M (LR-M) category describes hepatic lesions probably or definitely malignant, but not specific for hepatocellular carcinoma in at-risk patients. Differentiation among LR-M entities, particularly detecting cholangiocarcinoma-containi ...
Full textLink to itemCite
Journal ArticleHepatology · June 2021
BACKGROUND AND AIMS: Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North Amer ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · May 2021
Alcohol consumption in the setting of chronic HCV is associated with accelerated progression towards cirrhosis, increased risk of hepatocellular carcinoma and higher mortality. This analysis contextualizes how sociodemographic factors, chronic pain and dep ...
Full textLink to itemCite
Journal ArticleHepatology · March 2021
BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a heterogeneous cholangiopathy characterized by progressive biliary fibrosis. RNA sequencing of liver tissue from patients with PSC (n = 74) enrolled in a 96-week clinical trial was performed to ...
Full textLink to itemCite
Journal ArticleHepatol Commun · March 2021
This editorial reviews two articles in hepatology communications addressing challenges in the hepatitis C care cascade. ...
Full textLink to itemCite
Journal ArticleAlcohol Treat Q · 2021
Few studies exist on the change over time in positive and negative emotions during treatment for alcoholism disorders. We aimed to evaluate relationship between alcohol reduction and change in positive and negative emotions. Chronic HCV patients (n=174) wi ...
Full textLink to itemCite
Journal ArticleJ Infect Dis · November 27, 2020
The opioid epidemic has resulted in an increase in organ donors with hepatitis C virus (HCV) infection in the United States. With the development of direct-acting antiviral regimens that offer high sustained virologic response rates even in the setting of ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · November 2020
BACKGROUND: Malnutrition is common in patients with cirrhosis and is associated with poor outcomes after hepatic resection and liver transplantation. Transjugular intrahepatic portosystemic shunt (TIPS) is performed for complications of cirrhosis. AIM: To ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · October 2020
BACKGROUND & AIMS: The direct-acting antiviral combination glecaprevir/pibrentasvir has been approved by the Food and Drug Administration for 8 weeks of treatment in treatment-naïve patients with hepatitis C virus (HCV) infection without cirrhosis or with ...
Full textLink to itemCite
ConferenceLiver Transpl · September 2020
The aim of this study is to validate a proposed definition of sarcopenia in predicting wait-list mortality. We retrospectively evaluated 355 adults (age ≥18 years) with cirrhosis listed for first-time LT from January 1, 2010, to April 1, 2018 from our cent ...
Full textLink to itemCite
Journal ArticleHepatology · June 2020
BACKGROUND AND AIMS: Hepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions. APPROACH AND RESULTS: A total of 181 patients w ...
Full textLink to itemCite
Journal ArticleTransplantation · June 2020
BACKGROUND: Patients with nonalcoholic steatohepatitis (NASH) are waitlisted at older ages than individuals with other liver diseases, but the effect of age on liver transplantation (LT) outcomes in this population and whether it differs from other etiolog ...
Full textLink to itemCite
Journal ArticleAliment Pharmacol Ther · June 2020
BACKGROUND: Direct-acting anti-virals (DAA) are highly effective for hepatitis C virus (HCV) treatment, but perceived risks of medication non-adherence may restrict access to care. Digital medicine programme (DMP) has improved adherence and outcomes for so ...
Full textLink to itemCite
Journal ArticleClin Liver Dis (Hoboken) · April 2020
http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-4-reading-kapila a video presentation of this article. ...
Full textLink to itemCite
Journal ArticleJ Hepatol · March 2020
BACKGROUND & AIMS: Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to ...
Full textLink to itemCite
Journal ArticleClin Infect Dis · February 3, 2020
BACKGROUND: The causative relationship between the clearance of infections and long-term, health-related quality-of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted. The aim of this study was to assess long-term ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · February 2020
BACKGROUND & AIMS: Patients with hepatitis C virus (HCV) infections who achieve a sustained virologic response (SVR) to treatment have improved patient-reported outcomes (PROs). We compared post-treatment PRO scores between patients with chronic HCV infect ...
Full textLink to itemCite
Journal ArticleCurr HIV/AIDS Rep · February 2020
PURPOSE OF REVIEW: The prevalence of Hepatitis C virus (HCV) in the US incarcerated population is disproportionately high, and when inmates with infection are released back into the general population, they play a substantial role in the spread of disease. ...
Full textLink to itemCite
Journal ArticleJHEP reports : innovation in hepatology · February 2020
Background & aimsA DNA methylation (DNAm) signature derived from 353 CpG sites (the Horvath clock) has been proposed as an epigenetic measure of chronological and biological age. This epigenetic signature is accelerated in diverse tissue types in ...
Full textCite
Journal ArticleHepatology · December 2019
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridging fi ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · November 2019
BACKGROUND & AIMS: The incidence and outcomes of alanine aminotransferase (ALT) flares during the natural history of chronic HBV infection has not been determined in a large, racially heterogeneous group of patients in North America. METHODS: We collected ...
Full textLink to itemCite
Journal ArticleAm J Gastroenterol · October 2019
INTRODUCTION: Although there is substantial evidence suggesting poor health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC), similar data in nonalcoholic steatohepatitis (NASH) have not been fully assessed. The aim is to compare H ...
Full textLink to itemCite
ConferenceAmerican Journal of Gastroenterology · October 2019
INTRODUCTION:Patients with alcoholic hepatitis suffer from high rates of malnutrition and are at risk for hypophosphatemia due to poor dietary intake, renal wasting, and refeeding syndrom ...
Full textCite
Journal ArticleHepatology · September 2019
Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients wit ...
Full textLink to itemCite
Journal ArticleACG Case Rep J · August 2019
N-acetylcysteine (NAC) has been well studied in the treatment of acetaminophen-induced and select non-acetaminophen-induced liver failure. However, its role in the management of sickle cell hepatic crisis resulting in acute liver failure (ALF) is unknown. ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · July 2019
Hepatitis B e antigen (HBeAg) is an important serological marker of hepatitis B virus (HBV) infection and is associated with higher levels of viraemia, increased risk of infectivity to others and increased risk of hepatocellular carcinoma. We analysed HBeA ...
Full textLink to itemCite
Journal ArticleCurrent Hepatology Reports · June 15, 2019
Purpose of Review: Healthcare workers are a vulnerable population for exposure to a variety of bloodborne pathogens including hepatitis C (HCV). With the development of novel efficacious treatments for chronic HCV, the role of post-exposure prophylaxis (PE ...
Full textCite
Journal ArticleJ Hepatol · March 2019
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. NGM282, an engineered, non-tumorigenic FGF19 analogue, potently regulates CYP7A1-medi ...
Full textLink to itemCite
Journal ArticleHepatology · February 2019
Lysyl oxidase like-2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC). We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody directed against LOXL2 ...
Full textLink to itemCite
Journal ArticleSage Open · 2019
Chronic Hepatitis C (CHC) is the most common blood-borne infection in the U. S. Patients with CHC undergoing treatment face many challenges including adherence to medications and management of symptoms; health care practitioners are well positioned to faci ...
Full textLink to itemCite
Journal ArticleN C Med J · 2019
Prisoners in the United States are disproportionately affected by hepatitis C. Addressing the disease behind bars is crucial for curtailing the epidemic in the greater population. Effective strategies for testing and treatment are elucidated here. Recommen ...
Full textLink to itemCite
Journal ArticleJ Hepatol · December 2018
BACKGROUND & AIMS: Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogen ...
Full textLink to itemCite
Journal ArticleGastroenterology · October 2018
BACKGROUND & AIMS: Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients with adv ...
Full textLink to itemCite
Journal ArticleClin Transplant · October 2018
Human leukocyte antigen (HLA) serotyping is not considered to have significant impact on liver graft survival and does not factor into U.S. organ allocation. Immune-related liver diseases such as primary sclerosing cholangitis (PSC), autoimmune hepatitis ( ...
Full textLink to itemCite
Journal ArticleContemp Clin Trials · September 2018
INTRODUCTION: Among patients with hepatitis C virus (HCV) infection, alcohol synergistically increases the risk of cirrhosis, hepatocellular carcinoma, and death. Randomized controlled trials of integrated models of HCV-alcohol treatment have been recommen ...
Full textLink to itemCite
Journal ArticleHepatol Commun · September 2018
Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth f ...
Full textLink to itemCite
ConferenceHepatology · July 2018
UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC-specific patie ...
Full textLink to itemCite
Journal ArticleHealth Promot Pract · July 2018
An estimated 3 to 5 million Americans are chronically infected with hepatitis C virus (HCV), and approximately 75% of those persons were born between 1945 and 1965 (the so-called baby boomer generation). Because of the largely asymptomatic nature of HCV, u ...
Full textLink to itemCite
Journal ArticleExpert Opin Pharmacother · April 2018
INTRODUCTION: Direct acting antivirals (DAA's) have revolutionized the treatment of hepatitis C (HCV). However, questions persist concerning their efficacy in minority populations. AREAS COVERED: In this review, the authors review outcomes for treatment of ...
Full textLink to itemCite
Journal ArticleOpen Forum Infect Dis · January 2018
BACKGROUND: Direct-acting antivirals (DAA) as curative therapy for hepatitis C virus (HCV) infection offer >95% sustained virologic response (SVR), including in patients with human immunodeficiency virus (HIV) infection. Despite improved safety and efficac ...
Full textOpen AccessLink to itemCite
Journal ArticleDig Dis Sci · November 2017
BACKGROUND: There is increasing evidence for a heterogeneity of phenotypes in primary sclerosing cholangitis (PSC), but differences across the age spectrum in adults with PSC have not been well characterized. AIMS: To characterize phenotypic variations and ...
Full textLink to itemCite
Journal ArticleJ Magn Reson Imaging · September 2017
PURPOSE: To identify demographic and imaging features in magnetic resonance imaging (MRI) that are associated with upgrade of Liver Imaging Reporting and Data System (LI-RADS) category 4 (LR-4) observations to category 5 (LR-5), and to assess their effects ...
Full textLink to itemCite
Journal ArticleJ Hepatol · August 2017
BACKGROUND & AIMS: Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · July 2017
GOALS: To describe the complementary and alternative medicine (CAM) use in US adults with liver disease. BACKGROUND: The prevalence and patterns of CAM use among US adults with liver disease have not been well characterized. The 2012 National Health Interv ...
Full textLink to itemCite
Journal ArticleLiver Transpl · June 2017
Liver retransplantation in patients with primary sclerosing cholangitis (PSC) has not been well studied. The aims of this study were to characterize patients with PSC listed for and undergoing retransplantation and to describe the outcomes in these patient ...
Full textLink to itemCite
Journal ArticleGastroenterology · May 2017
Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic liver disease, are a leading cause of morbidity and mortality globally. Early identification of patients with cirrhosis at high ...
Full textLink to itemCite
Journal ArticlePatient Educ Couns · March 2017
OBJECTIVE: We tested an uncertainty self-management telephone intervention (SMI) with patients awaiting liver transplant and their caregivers. METHODS: Participants were recruited from four transplant centers and completed questionnaires at baseline, 10, a ...
Full textLink to itemCite
Journal ArticleTranspl Int · February 2017
This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once-daily simeprevir 150 mg + sofosbuvir 400 mg, with and without ribavirin 1000 mg. Primary endpoint was p ...
Full textLink to itemCite
Journal ArticleAnnu Rev Med · January 14, 2017
The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of ...
Full textLink to itemCite
Journal ArticleCurr Hepatol Rep · December 2016
Chronic hepatitis C virus (HCV) infection is burdensome in patients with chronic kidney disease and contributes to substantial liver-related and all-cause morbidity and mortality. HCV infection itself may cause kidney dysfunction, as exemplified through mi ...
Full textLink to itemCite
Journal ArticleJ Pain Symptom Manage · September 2016
CONTEXT: For end-stage liver disease (ESLD) patients, care focuses on managing the life-threatening complications of portal hypertension, causing high resource utilization. OBJECTIVES: To describe the end-of-life trajectory of hospitalized ESLD patients in ...
Full textLink to itemCite
Journal ArticleOpen Forum Infect Dis · September 2016
Background. Hepatitis C virus (HCV) infection is a leading cause of cirrhosis and the primary cause of liver transplantation in the United States, and coinfection with human immunodeficiency virus (HIV) increases the risk of comorbidities. However, health ...
Full textOpen AccessLink to itemCite
Journal ArticleAbdom Radiol (NY) · September 2016
PURPOSE: The purpose of this study was to characterize the MR imaging features and outcomes of liver imaging reporting and data system (LI-RADS) category 4 (LR4) nodules, with an emphasis on upgrade to category 5 (LR5) and development of contraindications ...
Full textLink to itemCite
Journal ArticleLiver Transpl · July 2016
Despite major improvements in access to liver transplantation (LT), disparities remain. Little is known about how distrust in medical care, patient preferences, and the origins shaping those preferences contribute to differences surrounding access. We perf ...
Full textOpen AccessLink to itemCite
Journal ArticleHepatology · February 2016
UNLABELLED: Black patients chronically infected with genotype 1 hepatitis C virus (HCV) have historically had lower rates of response to interferon-based treatment than patients of other races. In the phase 3 ION program, the single-tablet regimen of the N ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Natl Med Assoc · February 2016
The African American/Black population in the United States (US) is disproportionately affected by hepatitis C virus (HCV) and has lower response rates to current treatments. This analysis evaluates the participation of African American/Blacks in North Amer ...
Full textOpen AccessLink to itemCite
Journal ArticleGastroenterology · February 2016
BACKGROUND & AIMS: The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate th ...
Full textLink to itemCite
Journal ArticlePublic Health Rep · 2016
OBJECTIVES: The national Viral Hepatitis Action Plan recommends strengthening partnerships among health departments, community-based organizations, and health-care providers for hepatitis services. We implemented a hepatitis C virus (HCV) testing and linka ...
Full textLink to itemCite
Journal ArticleN C Med J · 2016
Gastrointestinal disorders range from life-threatening conditions to benign disorders, but all can impact the daily life of millions of Americans. For colorectal cancer, liver disease, and other conditions, early identification is important to avoid late-s ...
Full textLink to itemCite
Journal ArticleN Engl J Med · December 31, 2015
BACKGROUND: As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase. METHODS: We conducted a phase 3, open-label study involving both previously treated and previ ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · November 2015
The recent advances in hepatitis C virus (HCV) therapeutics have brought combinations of direct acting antiviral medications that offer interferon-free, well-tolerated regimens with sustained virologic response rates greater than 90% in clinical trials for ...
Full textLink to itemCite
Journal ArticleTher Adv Chronic Dis · November 2015
The burden of chronic hepatitis C virus (HCV) infection is significant and growing. HCV is considered one of the leading causes of liver disease worldwide and the leading cause of liver transplantation globally. While those infected is estimated in the hun ...
Full textOpen AccessLink to itemCite
Journal ArticleGastroenterology · September 2015
BACKGROUND & AIMS: There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. METHODS: In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, t ...
Full textLink to itemCite
Journal ArticleHepatology · August 2015
UNLABELLED: Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. In this study, we sought to better ...
Full textLink to itemCite
Journal ArticleClin Ther · August 2015
PURPOSE: Cirrhosis and its related complications remain a prominent global health concern despite advances in understanding and treating the disorder. Early diagnosis and intervention strategies may reduce the impact of cirrhosis; however, it can be diffic ...
Full textLink to itemCite
Journal ArticleJ Gastroenterol Hepatol · August 2015
BACKGROUND AND AIM: Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients without cirrhosis by a virus-mediated phenomenon. This study assessed the pre ...
Full textLink to itemCite
Journal ArticleJAMA · May 5, 2015
IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE: To determine the rates of sustained virologic response (SVR) in pati ...
Full textLink to itemCite
Journal ArticleJAMA · May 5, 2015
IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. OBJECTIVE: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · April 2015
BACKGROUND: The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect of ra ...
Full textLink to itemCite
Journal ArticleOpen Forum Infect Dis · April 2015
We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive HIV/HCV patients initiating their fi ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Hepatol · February 2015
BACKGROUND & AIMS: The safety profiles of boceprevir and telaprevir in the treatment of chronic hepatitis C, administered in academic and community centres across the United States, were evaluated. METHODS: In 90 medical centres, patients with chronic HCV ...
Full textLink to itemCite
Journal ArticleGastroenterology · January 2015
BACKGROUND & AIMS: Interferon alfa-based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated, associated with generally modest efficacy, and can interact with immunosuppressive agents. We eval ...
Full textLink to itemCite
Journal ArticleJ Hepatol · December 2014
BACKGROUND & AIMS: Peginterferon lambda-1a (Lambda) is a type-III interferon with similar antiviral activity to alfa interferons but with a diminished extrahepatic receptor distribution, reducing the risk for extrahepatic adverse events. METHODS: This was ...
Full textLink to itemCite
Journal ArticleN Engl J Med · May 15, 2014
BACKGROUND: High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. T ...
Full textLink to itemCite
Journal ArticleN Engl J Med · May 15, 2014
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepa ...
Full textLink to itemCite
Journal ArticleAm J Gastroenterol · May 2014
Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the second-generation protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi). The interferon-free regimen of s ...
Full textLink to itemCite
Journal ArticleN Engl J Med · April 17, 2014
BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. METHODS: We conducted a phase 3, randomized, op ...
Full textLink to itemCite
Journal ArticleJ Hepatol · April 2014
BACKGROUND & AIMS: Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribav ...
Full textLink to itemCite
Journal ArticleClin Infect Dis · April 2014
BACKGROUND: Myelosuppression due to pegylated interferon (peg-IFN) is common during treatment for hepatitis C virus. The relationship between infection risk and decreases in leukocyte lines, however, is not well established. The objective of this analysis ...
Full textLink to itemCite
Journal ArticleClin Pharmacol Ther · February 2014
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV th ...
Full textLink to itemCite
Journal ArticleTop Antivir Med · 2014
Treatment of hepatitis C virus (HCV)-infected patients with cirrhosis remains challenging. Biopsy to stage liver fibrosis remains the standard for identifying cirrhosis, although the noninvasive technique of transient elastography is promising in this rega ...
Link to itemCite
Journal ArticlePLoS One · 2014
AIM: Sustained virologic response (SVR) can be attained with boceprevir plus peginterferon alfa and ribavirin (PR) in up to 68% of patients, and short duration therapy is possible if plasma HCV RNA levels are undetectable at treatment week 8 (TW8 response) ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · December 2013
Anaemia frequently complicates peginterferon/ribavirin therapy for chronic hepatitis C infection. Better prediction of anaemia, ribavirin dose reduction or erythropoietin (EPO) need, may enhance patient management. Inosine triphosphatase (ITPA) genetic var ...
Full textLink to itemCite
ConferencePharmacogenet Genomics · November 2013
INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · November 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in ...
Full textLink to itemCite
Journal ArticleLancet Infect Dis · May 2013
BACKGROUND: Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuvir, a uridine ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · March 2013
The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and bocepr ...
Full textLink to itemCite
Journal ArticleJ Comput Assist Tomogr · 2013
OBJECTIVE: The objectives of this study were to explore utilization of multi-detector row computed tomography (MDCT) in screening for hepatocellular carcinoma (HCC) and to modify a liver CT protocol with a goal of dose reduction. METHODS: An electronic mai ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · 2013
GOALS: To evaluate differences in metrics of quality and site performance in academic and community sites participating in a multicenter study. BACKGROUND: In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Ther ...
Full textLink to itemCite
Journal ArticleInfect Dis Clin North Am · December 2012
In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial impr ...
Full textLink to itemCite
Journal ArticleAIDS Patient Care STDS · September 2012
Abstract Health care utilization for HIV-1-infected patients appears to be declining in the United States as a result of highly active antiviral therapy (HAART); yet the opposite appears true in the HIV/hepatitis C virus (HCV) coinfected population. The re ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · August 2012
BACKGROUND: Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined. AIM: We sought to validate thes ...
Full textLink to itemCite
Journal ArticleHepatology · August 2012
UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (P ...
Full textLink to itemCite
Journal ArticleHepatology · July 2012
UNLABELLED: Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype-dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insul ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · May 2012
Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. IL28B has been linked with LDL-C ...
Full textLink to itemCite
Journal ArticleClin Liver Dis · May 2012
Patients with chronic liver disease face greater risk of perioperative morbidity and mortality, with the greatest risk among patients with cirrhosis. Both the Child-Pugh score and the Model for End-Stage Liver Disease have been evaluated as predictors of p ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · April 2012
BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment. AIMS: This prospective cohort study examined the feasibi ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Hepatol · February 2012
BACKGROUND & AIMS: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related ...
Full textLink to itemCite
Chapter · January 1, 2012
The likelihood of response for an individual patient treated with standard pegylated interferon alpha and ribavirin for hepatitis C is impacted by a combination of viral factors and patient factors. Infection with viral genotypes 2 or 3 is favorable for re ...
Full textCite
Journal ArticleBiostatistics · January 2012
Mixed models are commonly used to represent longitudinal or repeated measures data. An additional complication arises when the response is censored, for example, due to limits of quantification of the assay used. While Gaussian random effects are routinely ...
Full textLink to itemCite
Journal ArticleValue Health · 2012
BACKGROUND: Shortened courses of treatment with pegylated interferon alfa and ribavirin for patients with hepatitis C virus infection who experience rapid virologic response can be effective in appropriately selected patients. The cost-effectiveness of tru ...
Full textLink to itemCite
Journal ArticleAntivir Ther · 2012
In 2011, the protease inhibitors boceprevir and telaprevir were approved in the United States and European Union for the treatment of hepatitis C infection. While remarkably effective, the newly approved therapies are also accompanied by additional side ef ...
Full textLink to itemCite
Journal ArticleCurrent Hepatitis Reports · January 1, 2012
The discovery of genetic variants near the gene for IL28B has provided new insight into the biology of hepatitis C infection and response to treatment with pegylated interferon alpha and ribavirin. Patients that carry the favorable CC genotype for SNP rs12 ...
Full textCite
Journal ArticleJ Hepatol · December 2011
BACKGROUND & AIMS: IL28B polymorphisms have been associated with both treatment induced and spontaneous clearance of hepatitis C virus (HCV). We previously found that LDL cholesterol levels were higher in chronic hepatitis C (CHC) patients with the CC geno ...
Full textLink to itemCite
Journal ArticleExpert Rev Anti Infect Ther · December 2011
Telaprevir is an NS3/4A protease inhibitor that has recently received US FDA approval for the treatment of chronic HCV infection. Telaprevir is given in combination with peg-IFN-α and ribavirin and is indicated for both treatment-naive and treatment-experi ...
Full textLink to itemCite
Journal ArticleAIDS Behav · November 2011
Accurate HCV knowledge is lacking among high-risk groups, including people with HIV/AIDS (PLWHA). Liver disease primarily due to HCV has emerged as a serious cause of mortality among PLWHA. We used an Interrupted Time Series design to evaluate a social-eco ...
Full textLink to itemCite
Journal ArticleHepatology · November 2011
Featured Publication
UNLABELLED: Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment. This study evaluated the safety and efficacy of telaprevir-based ...
Full textLink to itemCite
Journal ArticleGastroenterol Clin North Am · September 2011
The HCV viral life cycle provides targets for drug development at virtually every step, and many new drugs aimed at these targets are currently being developed. Clinical practice takes a major step forward this year with the arrival of telaprevir and bocep ...
Full textLink to itemCite
Journal ArticleHepatology · July 2011
UNLABELLED: Black Americans are disproportionally infected with hepatitis C virus (HCV) and are less likely than whites to respond to treatment with peginterferon (PEG-IFN) plus ribavirin (RBV). The impact of race on HCV treatment eligibility is unknown. W ...
Full textLink to itemCite
Journal ArticleN Engl J Med · June 23, 2011
BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · April 2011
Featured Publication
Previous studies of chronic hepatitis C virus (HCV) treatment have demonstrated variations in response among racial and ethnic groups including poorer efficacy rates among African American and Hispanic patients. The individualized dosing efficacy vs flat d ...
Full textLink to itemCite
Journal ArticleN Engl J Med · March 31, 2011
BACKGROUND: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV- ...
Full textLink to itemCite
Journal ArticleGastroenterol Hepatol (N Y) · March 2011
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of wh ...
Link to itemCite
Journal ArticleCurrent Hepatitis Reports · March 1, 2011
Recently, single-nucleotide polymorphisms near the IL28B gene have been identified as important in predicting treatment response and spontaneous clearance of the hepatitis C virus (HCV). In the less than 12 months since the initial genetic discoveries, our ...
Full textCite
Journal ArticleHepatology · February 2011
UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepati ...
Full textLink to itemCite
Journal ArticleDig Dis Sci · December 2010
Featured Publication
OBJECTIVES: The treatment of choice for HCC with cirrhosis is liver transplantation (LT). We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, an ...
Full textLink to itemCite
Journal ArticleHepatology · October 2010
UNLABELLED: Ribavirin-induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (SVR) rates in the treatment of patients with chronic hepatitis C. The study aimed to determine if weight-based dosing of taribavirin (TBV), an ...
Full textLink to itemCite
Journal ArticleGastroenterology · October 2010
BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic ane ...
Full textLink to itemCite
Journal ArticleGastroenterology · October 2010
BACKGROUND & AIMS: The current standard of care for patients with chronic hepatitis C virus (HCV) genotype 1 is once-weekly pegylated interferon-α (Peg-IFNα) plus daily ribavirin for 48 weeks. We evaluated the efficacy/safety of albinterferon alfa-2b (albI ...
Full textLink to itemCite
Journal ArticleRes Nurs Health · October 2010
We identified trajectories of illness uncertainty in chronic hepatitis C patients and examined their association with fatigue levels during 12 months of disease monitoring without treatment (watchful waiting). Sixty-two men and 63 women completed uncertain ...
Full textLink to itemCite
Journal ArticleHepatology · September 2010
Featured Publication
UNLABELLED: Interferon lambda 1 (IFN-lambda1) is a type III IFN that produces intracellular responses similar to those of IFN-alpha but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an ...
Full textLink to itemCite
Journal ArticleWorld J Gastroenterol · August 28, 2010
Coinfection with hepatitis B virus (HBV) is not uncommon in human immunodeficiency virus (HIV)-infected individuals and patients with HIV-HBV coinfection are at high risk for progression of liver disease. Current guidelines regarding the treatment of HIV i ...
Full textLink to itemCite
Journal ArticleComplement Ther Clin Pract · August 2010
BACKGROUND: The use of complementary and alternative medicine (CAM) is expanding globally. However, prevalence of its use by patients with chronic hepatitis C (CHC) remains unclear. METHODS: An exploratory, descriptive study was conducted using a questionn ...
Full textLink to itemCite
Journal ArticleNeurogastroenterol Motil · August 2010
BACKGROUND: Lung transplantation has become an effective therapeutic option for selected patients with end stage lung disease. Long-term survival is limited by chronic rejection manifest as bronchiolitis obliterans syndrome (BOS). The aspiration of gastric ...
Full textLink to itemCite
Journal ArticleSouth Med J · July 2010
OBJECTIVE: Liver disease associated with hepatitis C virus (HCV) is a serious cause of mortality among people living with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) (PLWHA). Little is known about the HCV knowledge of PLWHA. ...
Full textLink to itemCite
Journal ArticleGastroenterology · July 2010
BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatmen ...
Full textLink to itemCite
Journal ArticleGastroenterology · June 2010
BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infections are treated with pegylated interferon and ribavirin (PEG-IFN/RBV), which is effective in less than 50% of those infected with HCV genotype 1. Genome-wide association studies have l ...
Full textLink to itemCite
Journal ArticleHepatology · June 2010
UNLABELLED: Recently, genetic polymorphisms occurring in the interferon (IFN)-lambda gene region were associated with response to IFN-based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with de ...
Full textLink to itemCite
Journal ArticlePediatr Blood Cancer · May 2010
Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term l ...
Full textLink to itemCite
Journal ArticleN Engl J Med · April 8, 2010
Featured Publication
BACKGROUND: Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment. METHODS: We randomly assigned patients with HCV genotype 1 ...
Full textLink to itemCite
Journal ArticleNature · March 18, 2010
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and i ...
Full textLink to itemCite
Journal ArticleGastroenterol Nurs · 2010
The use of mind-body medicine by patients with chronic hepatitis C has not been reported. The prevalence and reasons for using mind-body medicine and prayer among a cohort of patients with chronic hepatitis C are described. Use of mind-body medicine and pr ...
Full textLink to itemCite
Journal ArticleNature · September 17, 2009
Featured Publication
Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN ...
Full textLink to itemCite
Journal ArticleN Engl J Med · August 6, 2009
Featured Publication
BACKGROUND: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. METHODS: At 118 sit ...
Full textLink to itemCite
Journal ArticleN Engl J Med · April 30, 2009
Featured Publication
BACKGROUND: Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV R ...
Full textLink to itemCite
Journal ArticleClin Gastroenterol Hepatol · February 2009
BACKGROUND & AIMS: Pegylated interferon alfa-2a/2b is used in combination with ribavirin to treat patients with chronic hepatitis C (CHC), although many do not achieve a sustained virologic response (SVR). Albinterferon alfa-2b, a recombinant protein consi ...
Full textLink to itemCite
Journal ArticlePsychosomatics · 2009
BACKGROUND: Chronic hepatitis C (CHC) is the most common blood-borne infection in the United States, but little is known about illness uncertainty in these patients. OBJECTIVE: The authors examined the constructs of illness uncertainty. METHOD: In this cro ...
Full textLink to itemCite
Journal ArticleJAMA · November 26, 2008
CONTEXT: In February 2002, the allocation system for liver transplantation became based on the Model for End-Stage Liver Disease (MELD) score. Before MELD, black patients were more likely to die or become too sick to undergo liver transplantation compared ...
Full textLink to itemCite
Journal ArticleJ Hepatol · August 2008
Featured Publication
BACKGROUND/AIMS: This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin. METHODS: Twelve treatment-naïve patients with chronic genotype 1 hepatitis C virus infection received tela ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · August 2008
GOALS: We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia. BACKGROUND: Gastroesophageal variceal ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · June 3, 2008
Featured Publication
Chronic hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with an estimated overall prevalence of 3.2 million persons (1.3%) and prevalence peaks between age 40 to 49 years (1). The worldwide prevalence of HCV ...
Full textLink to itemCite
Journal ArticleLiver Transpl · February 2008
Featured Publication
In the current system of allocation, patients awaiting orthotopic liver transplantation (OLT) remain at risk of developing de novo hepatocellular carcinoma (HCC) and removal from the waiting list. Using the United Network for Organ Sharing database, we cal ...
Full textLink to itemCite
Journal ArticleTranspl Infect Dis · December 2007
Clostridium difficile-associated diarrhea (CDAD) has a wide spectrum of disease severity. Studies have implicated immunosuppressants as a risk factor for severe disease. We hypothesized that solid organ transplant (SOT) patients with CDAD would be at great ...
Full textLink to itemCite
Journal ArticleHepatology · November 2007
UNLABELLED: CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-p ...
Full textLink to itemCite
Journal ArticlePractical Gastroenterology · August 1, 2007
This article summarizes current treatment recommendations and discusses alternative approaches to therapy in patients with hepatitis C. ...
Cite
Journal ArticleClin Liver Dis · November 2006
Featured Publication
Hepatitis C virus (HCV) is a major cause of liver disease worldwide and is the most common chronic blood-borne infection in the United States. Experience has shown that the epidemiology and the response to treatment of HCV vary in certain patient groups. D ...
Full textLink to itemCite
Journal ArticleJ Hepatol · October 2006
BACKGROUND/AIMS: Azathioprine is a key drug in the management of autoimmune hepatitis (AIH), with effects mediated via conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP), the latter controlled by thiopurine methyltransferase (TPMT). Our ...
Full textLink to itemCite
Journal ArticleCurrent Hepatitis Reports · August 1, 2006
Hepatitis C is the most common blood-borne infection in the United States and the most common cause of liver-related morbidity and mortality. There are significant racial/ethnic disparities in the epidemiology, natural history, and treatment outcomes of he ...
Full textCite
Journal ArticleJ Viral Hepat · May 2006
Given that the complications of hepatitis C are due to fibrosis, we hypothesized that the antifibrotic effects of interferon gamma on stellate cells would lead to beneficial effects in patients with hepatitis C. Thus, we evaluated the safety and efficacy o ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · 2006
GOALS: The objective of our investigation was to examine the clinical utilization of digital rectal examination (DRE) and fecal occult blood testing (FOBT) at hospital admission. BACKGROUND: DRE at the time of hospital admission is frequently accompanied b ...
Full textLink to itemCite
Journal ArticleClin Liver Dis · November 2005
Treatment options for hepatitis C virus (HCV) infection have improved significantly in recent years, however, treatment recommendations came from large clinical trials of highly selected patient populations. HCV infection has increased prevalence in Africa ...
Full textLink to itemCite
Journal ArticleTransplantation · July 15, 2005
Featured Publication
BACKGROUND: Chronic hepatitis C virus (HCV) infection is the most common indication for orthotopic liver transplantation (OLT) in the United States. Recent studies from selected centers have suggested that older donor age is associated with worse outcomes ...
Full textLink to itemCite
Journal ArticleClin Transplant · April 2005
Sirolimus is emerging as a popular immunosuppressive agent for patients undergoing solid organ and pancreatic cell transplantation. Here, we report the clinical courses of three patients receiving sirolimus who developed aggressive gastroduodenal ulcer dis ...
Full textLink to itemCite
Journal ArticleAm J Gastroenterol · February 2005
OBJECTIVES: In hepatitis C virus (HCV)-infected patients receiving pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy, anemia is a well-known side effect. The purpose of this study was to describe the time course and extent of hemoglobin (H ...
Full textLink to itemCite
Journal ArticleN Engl J Med · May 27, 2004
Featured Publication
BACKGROUND: Several small studies have reported a lower response rate to interferon alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which ...
Full textLink to itemCite
Journal ArticleTransplant Proc · June 2003
Electrical storm has not been well described in liver transplant patients. We present a case of sympathetically mediated recurrent ventricular fibrillation in a young patient transplanted for acute Wilson's disease. This case highlights the role of the sym ...
Full textLink to itemCite
Journal ArticleAm J Transplant · May 2003
Orthotopic liver transplantation is the only definitive therapeutic option in patients with primary sclerosing cholangitis (PSC) and end-stage liver disease. However, PSC recurs in up to 20% of patients transplanted for this indication. To date, no patient ...
Full textLink to itemCite
Journal ArticleLiver Transpl · October 2002
With the recent transition of the liver transplant allocation system to the Model for End-Stage Liver Disease, a major change is its reliance entirely on objective criteria. In previous reports, potential donor families and members of the transplant commun ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · July 2002
GOALS: To survey clinicians regarding current liver biopsy practice patterns. BACKGROUND: Although the hepatitis C epidemic has increased the proportion of hepatology in general gastroenterology practice, many clinicians express concern regarding the risks ...
Full textLink to itemCite
Journal ArticlePlanta · July 2002
Nonarticulated laticifers are latex-containing cells that elongate indefinitely and grow intrusively between the walls of meristematic cells. To identify biochemical mechanisms involved in the growth of nonarticulated laticifers, we have analyzed the distr ...
Full textLink to itemCite
Journal ArticleJ Clin Gastroenterol · March 2002
GOAL: To assess the number of chronic hepatitis C patients eligible for therapy. BACKGROUND: Recent studies have shown improved response rates to treatment of chronic hepatitis C infection. However, treatment with interferon alfa has major side effects, an ...
Full textLink to itemCite
Journal ArticleAm J Gastroenterol · May 2001
OBJECTIVES: The ileal pouch anal anastomosis is a safe and effective procedure but is also associated with pouchitis, small bowel obstruction, and incontinence. We prospectively evaluated the health-related quality of life using generic and disease-specifi ...
Full textLink to itemCite
Journal ArticleJ Gen Intern Med · February 2001
OBJECTIVE: To determine if a visual intervention (medication grid) delivered to physicians can reduce medication regimen complexity. DESIGN: Nonrandomized, controlled trial. SETTING: Veterans Affairs medical center. PATIENTS/PARTICIPANTS: Eight hundred thi ...
Full textLink to itemCite
Journal ArticleProtoplasma · 2001
Asclepias speciosa Torr. has latex-containing cells known as nonarticulated laticifers. In stem sections of this species, we have analyzed the cell walls of nonarticulated laticifers and surrounding cells with various stains, lectins, and monoclonal antibo ...
Full textLink to itemCite
Journal ArticleSemin Gastrointest Dis · April 2000
Although early data suggested that chronic hepatitis C virus infection carried little risk, studies with longer duration of infection have reported concerning results. Of patients with acute infection, approximately 80% will develop chronic infection. The ...
Link to itemCite
Journal ArticleVirology · October 15, 1996
Antisera to 21 synthetic peptides containing hydrophilic sequences of simian immunodeficiency virus strain mac251 (SIVmac251) gp120 and gp32 were tested for the ability to neutralize SIVmac251. Goat antisera raised to peptides SP-1 and SP-1V containing the ...
Full textLink to itemCite
Journal ArticleJ Virol · October 1992
Twelve synthetic peptides containing hydrophilic amino acid sequences of human T-cell lymphotropic virus type I (HTLV-I) envelope glycoprotein were coupled to tetanus toxoid and used to raise epitope-specific antisera in goats and rabbits. Low neutralizing ...
Full textLink to itemCite